Sleep cycles oscillated with lunar phases: nights before a full moon, people went to bed later and slept less, wrist actimetry showed. (Science Advances)
An afternoon snooze was linked to better cognitive function in older adults. (General Psychiatry)
The FDA extended its review period for Biogen’s investigational Alzheimer’s drug aducanumab by 3 months, until June 7.
Biogen also announced the FDA approved its peginterferon beta-1a (Plegridy) intramuscular administration for MS.
Another study tied APOE4 genotype to the presence and clinical severity of SARS-CoV-2 infection in older adults. (Gerontology)
NIH launched NeuroCOVID, a database to track neurological symptoms associated with COVID-19.
Serum neurofilament light, a marker of neuronal damage, correlated with several MS patient-perceived physical outcomes. (Annals of Clinical and Translational Neurology)
Deep learning software detected age-related cognitive impairment using only photos of patients’ faces. (Aging)
Patients with isolated dystonia had an increased prevalence of suicidal behavior compared with the general population, survey data showed. (Neurology)
Amantadine (Gocovri) picked up a second indication and now can be used with levodopa/carbidopa to treat “off” Parkinson’s disease episodes, Adamas Pharmaceuticals said. The drug already was approved for dyskinesia motor complications.
Brain celebrated the 400th anniversary of the birth of Thomas Willis, founder of clinical neurology.
Source: MedicalNewsToday.com
